Pseudoephedrine no boost to performance

June 30, 2009

(PhysOrg.com) -- Many top-level cyclists may be putting their health at risk for no competitive gain by taking pseudoephedrine, according to new research.

Dr Toby Mündel and Dr Steve Stannard, from the Institute of Food, Nutrition and Human Health detail the research in a paper soon to be published in the European Journal of Sport Science.

The researchers tested eight well-trained cyclists who performed two time trials in the laboratory. Ninety minutes before each trial they were given either a placebo or approximately three times the usually prescribed dose of pseudoephedrine.

“Our results showed that pseudoephedrine did not have a noticeable effect on the cyclists' performance,” says Dr Mündel.

Pseudoephedrine, commonly used in cold medicines but also to make the illegal drug or P, was taken off the banned substance list by the World Anti-Doping Agency five years ago.

New Zealand is now considering a total ban, after Prime Minister John Key asked advisers to look into whether pseudoephedrine could be removed from cold and flu remedies without rendering those drugs ineffective.

Dr Mündel says some of those participating in the research had unpleasant side effects. “One vomited once he had completed the test and said he had muscle cramps and felt decidedly hotter. Others also commented that they suffered slight nausea."

Dr Mündel says the research shows there may be some risk. “If riders are already pushing themselves hard, taking pseudoephedrine could increase their heart rate further.

“The reason we decided to look at it in the sporting arena is the same reason the government is looking at banning, it, because it can be abused. Our research seems to suggest the risks outweigh the benefits.”

Provided by Massey University (news : web)

Related Stories

Recommended for you

FDA's program to speed up drug approval shaved nearly a year off the process

December 7, 2017
Speeding the pace at which potentially lifesaving drugs are brought to market was a rallying cry for Donald Trump as a candidate, and is a stated priority of his Food and Drug Administration commissioner, Dr. Scott Gottlieb. ...

Dangers of commonly prescribed painkillers highlighted in study

December 6, 2017
Commonly prescribed painkillers need to be given for shorter periods of time to reduce the risk of obesity and sleep deprivation, a new study has revealed.

Viagra goes generic: Pfizer to launch own little white pill

December 6, 2017
The little blue pill that's helped millions of men in the bedroom is turning white. Drugmaker Pfizer is launching its own cheaper generic version of Viagra rather than lose most sales when the impotence pill gets its first ...

Surgery-related opioid doses can drop dramatically without affecting patients' pain

December 6, 2017
Some surgeons might be able to prescribe a third of opioid painkiller pills that they currently give patients, and not affect their level of post-surgery pain control, a new study suggests.

Four-fold jump in deaths in opioid-driven hospitalizations

December 4, 2017
People who end up in the hospital due to an opioid-related condition are four times more likely to die now than they were in 2000, according to research led by Harvard Medical School and published in the December issue of ...

Researchers identify information gaps about opioid antidote naloxone

November 27, 2017
The nation's opioid epidemic kills 91 people a day, according to the U.S. Centers for Disease Control and Prevention. The death toll would be even higher, were it not for emergency responders' heavy reliance on naloxone as ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.